title: Treatment of toxic epidermal necrolysis and a review of six cases.
abstract: Six cases of drug-induced toxic epidermal necrolysis treated in a burns unit are presented. The mean skin loss was 67.3 per cent of the total body surface area. Two patients developed renal failure and two had ocular symptoms. The mortality rate was 50 per cent, with two patients dying from septicaemia and one from respiratory and renal failure. The diagnosis of toxic epidermal necrolysis can be confirmed by skin biopsy. We recommend that this disease is treated in a burns unit so that both adequate wound care and essential intensive supportive treatment can be given. Antibiotics are indicated only for specific infections such as septicaemia or pneumonia. Steroids have been shown to increase greatly the mortality from septic complications and are not recommended. The mortality ranges from 10 per cent to 70 per cent and bad prognostic factors include increasing age, greater than 50 per cent of body surface skin loss and neutropenia.
authors: McIndoe Burns Unit, Queen Victoria Hospital, East Grinstead, UK.
authors: D J
authors: DJ
authors: Ward
authors: E C
authors: EC
authors: Krzeminska
authors: N S
authors: NS
authors: Tanner
mesh_terms: D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000009:adverse effects; D019980:Amoxicillin-Potassium Clavulanate Combination; D000962:Antimalarials / Q000009:adverse effects; D002746:Chlorpromazine / Q000009:adverse effects / Q000031:analogs & derivatives; D002969:Clavulanic Acids / Q000009:adverse effects; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000009:adverse effects; D012189:Retrospective Studies; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D013413:Sulfadoxine / Q000009:adverse effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects; D015031:Zimeldine / Q000009:adverse effects
chemical_list: D000962:Antimalarials; D002969:Clavulanic Acids; D004338:Drug Combinations; D007004:Hypoglycemic Agents; C026714:opromazine; C001205:fanasil, pyrimethamine drug combination; D015031:Zimeldine; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013413:Sulfadoxine; D002746:Chlorpromazine; D011739:Pyrimethamine